Announcements Trials
Browse Landscape

Phase

Phase 3 52Phase 2 23Phase 2/3 9Phase 1 8Phase 1/2 6Phase NA 4Phase 4 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Neoplasms 66Breast Neoplasms 64Prostatic Neoplasms 46Carcinoma, Non-Small-Cell Lung 40Neoplasm Metastasis 23Colorectal Neoplasms 21Multiple Myeloma 20Pain 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 16Anemia 16Keratosis, Actinic 15Lung Neoplasms 14Cancer Pain 14Lymphoma, Non-Hodgkin 12Lymphoma, Follicular 11Leukemia 11Leukemia, Lymphocytic, Chronic, B-Cell 10Carcinoma, Renal Cell 10Carcinoma, Hepatocellular 9Carcinoma 9Neuroendocrine Tumors 8Melanoma 8Lymphoma 8Ovarian Neoplasms 7Leukemia, Myeloid, Acute 7Uterine Cervical Neoplasms 6Recurrence 6Gastrointestinal Stromal Tumors 6Stomatitis 5Stomach Neoplasms 5

Interventions

rozanolixizumab 1ravulizumab 1Prednisone 1Prednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × INDUSTRY × Myasthenia Gravis × Clear all
NCT07246564 2026-05-22

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 4 Recruiting
40 enrolled

Myasthenia Gravis

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡